Skip to content

Efficacy of Preoperative Intravenous Tranexamic Acid Before Caesarean Section in Placenta Previa

Efficacy of Preoperative Intravenous Tranexamic Acid Before Caesarean Section in Placenta Previa : a randomized double blind control trial

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20220930003
Enrollment
60
Registered
2022-09-30
Start date
2021-07-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

intraoperative blood loss in pregnant woman undergoes caesarean section due to placenta previa Keyword: Tranexamic acid, preoperative, placenta previa, intraoperative blood loss, caesarean section

Interventions

Group 1 patients received the drug labeled T1 that was 1 g tranexamic acid of concentration (250mg/5ml) 20 ml in 80 ml NSS intravenous drip in 5 min before the skin incision. , Group T2 patients recei
Placebo Comparator Drug,Placebo Comparator Drug

Sponsors

none
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. All pregnant woman with placenta previa diagnosed by transabdominal or transvaginal ultrasound(if not clearly by TAS) confirmed at GA 28 week by obstetricians 3. undergoing caesarean delivery for placenta previa include elective c/s at term (37+ week) or emergency c/s due to placenta previa 4. Repeat ultrasound confirm before caesarean section 5. Age > 18 year and already informed consent

Exclusion criteria

Exclusion criteria: 1. Allergic patient to transamine 2. Undergo caesarean section due to placenta previa before GA 28 week 3. follow up by ultrasound during antenatal care and diagnosis was changed 4. Patient with showed any sign of adherent placenta on ultrasound 5. Patient with active cardiac, hepatic, renal disease 6. patient with risk factor for VTE such as prior VTE, thrombophilia disease**, hematologic cancer, immobilize patient, first degree relative history of VTE, morbid obesity BMI>40 7.Underlying disease of Coagulopathy, thrombocytopenia or on anticoagulant 8. patient cannot make decision

Design outcomes

Primary

MeasureTime frame
intraoperative blood loss intraoperative intraoperative blood loss measured by amount of blood in suction add with diffrent weight between soaked gauze and dry gauze

Secondary

MeasureTime frame
incidence of PPH 24 hour postpartum measured blood loss 24 hr postpartum more than 1000 ml

Countries

Thailand

Contacts

Public Contactsupakorn chaiyakarn

chonburi hospital

palm_cream@hotmail.com0819133454

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026